Fimasartan/rosuvastatin

Drug Profile

Fimasartan/rosuvastatin

Alternative Names: BKC-003; Rosuvastatin/fimasartan

Latest Information Update: 10 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Fluorobenzenes; Pyrimidines; Pyrimidinones; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Dyslipidaemias; Hypertension

Most Recent Events

  • 31 Aug 2016 Preregistration for Dyslipidaemias in South Korea (PO) (Boryung pharmaceuticals pipeline, August 2016)
  • 31 Aug 2016 Preregistration for Hypertension in South Korea (PO) (Boryung pharmaceuticals pipeline, August 2016)
  • 01 Jun 2016 Boryung Pharmaceutical completes a phase I pharmacokinetics trial for Hypertension (In volunteers) in USA (NCT02704702)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top